Our Innovative Technology

The Company has two proprietary platforms. 1) The Tetrabody Platform is used to create multi-targeted, highly potent IgGs based on human VH or humanized VHH domain antibodies. 2) Bioengineered Probiotic Yeast Medicines (BioPYM) platform to create GMO probiotic yeast that efficiently express protein therapeutics. These live yeast are designed for encapsulation and oral administration for the targeted treatment of gastro-intestinal diseases.

 

BioPYM Platform Overview: The BioPYM platform enables highly efficient expression and secretion of therapeutic proteins, including antibodies, enzymes, cytokines, and hormones.  The end drug product is an oral capsule containing live, lyophilized therapeutic yeast. The orally administered yeast micro-factories activate and make therapeutics in the gut at the disease location. The yeast itself acts symbiotically with flora in the gastrointestinal tract, beneficially modulating gut function and immune homeostasis. Yeast will not colonize, so PK is controllable, and therapy may be administered chronically while symptoms persist. In addition, BioPYM yeast can be  used concurrently with antibiotics and will not trigger drug-resistance.  

  

BioPYM yeast platform is engineered with a “plug-n-play” genomic insertion site; thus each drug candidate will be the same parental yeast line with variation in the genomic insert. We will enjoy significant redundancy for cost and time savings with respect to CMC, formulation, packaging and stability studies.  Our manufacturing will be considerably less expensive and much faster than traditional biologics which must be highly purified for injection. We also expect learnings from our first BioPYM product will de-risk and lower costs and time for our following BioPYM drug candidates.